Latest Ratios: P/E Ratio -1.2x · EV/EBITDA N/A · ROE -35.2%. (2016–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $7M | $5M | $9M | $164M | $365M | — | — | — | — | — |
| Enterprise Value | $2M | $5M | $822304 | $3M | $162M | $363M | — | — | — | — | — |
| P/E Ratio → | -1.19 | — | — | — | — | 482.45 | — | — | — | — | — |
| P/S Ratio | 0.52 | 0.99 | 0.52 | 0.93 | 15.03 | 27.30 | — | — | — | — | — |
| P/B Ratio | 0.41 | 0.85 | 0.60 | 0.95 | 24.65 | 50.81 | — | — | — | — | — |
| P/FCF | — | — | — | — | 330.09 | 60816.36 | — | — | — | — | — |
| P/OCF | — | — | — | — | 297.69 | 39825.06 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.69 | 0.09 | 0.34 | 14.84 | 27.15 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | 311.66 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 343.61 | — | — | — | — | — |
| EV / FCF | — | — | — | — | 325.95 | 60475.14 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 14.6% | 14.6% | 13.6% | 13.6% | 11.5% | 16.4% | 15.1% | 44.0% | 13.5% | 73.2% | — |
| Operating Margin | -42.5% | -42.5% | -16.5% | -26.5% | -2.7% | 7.9% | 11.2% | -217.2% | 28.2% | -118.8% | — |
| Net Profit Margin | -40.2% | -40.2% | -16.8% | -26.9% | -3.3% | 5.6% | 9.6% | -194.1% | 12.5% | -114.9% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -35.2% | -35.2% | -17.8% | -32.2% | -5.1% | 10.9% | 28.1% | -18.6% | 3.3% | -265.2% | — |
| ROA | -30.3% | -30.3% | -14.6% | -26.1% | -3.9% | 7.6% | 19.3% | -17.1% | 1.8% | -19.4% | -3211.5% |
| ROIC | -44.8% | -44.8% | -29.4% | -45.9% | -4.5% | 17.3% | 43.9% | -31.9% | 44.9% | — | — |
| ROCE | -36.7% | -36.7% | -17.2% | -31.4% | -4.2% | 15.1% | 32.2% | -19.9% | 7.1% | -261.3% | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.02 | 0.08 | 0.05 | — | — |
| Debt / EBITDA | — | — | — | — | — | 0.07 | 0.09 | — | 0.82 | — | — |
| Net Debt / Equity | — | -0.26 | -0.50 | -0.60 | -0.31 | -0.29 | -0.40 | -0.69 | -0.38 | -8.87 | — |
| Net Debt / EBITDA | — | — | — | — | — | -1.76 | -1.94 | — | -5.74 | — | — |
| Debt / FCF | — | — | — | — | -4.14 | -341.22 | -20.33 | — | — | -19.79 | — |
| Interest Coverage | -151.73 | -151.73 | -74.42 | -186.20 | -23.33 | 81.39 | 112.60 | — | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($176046)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.46 | 10.46 | 3.81 | 4.93 | 3.00 | 3.04 | 2.37 | 17.11 | 20.64 | 0.85 | 0.02 |
| Quick Ratio | 9.16 | 9.16 | 3.10 | 4.24 | 2.52 | 2.39 | 2.02 | 16.97 | 20.40 | 0.82 | 0.02 |
| Cash Ratio | 4.57 | 4.57 | 2.24 | 3.64 | 1.06 | 0.91 | 0.83 | 16.66 | 20.04 | 0.71 | 0.02 |
| Asset Turnover | — | 0.80 | 0.91 | 0.86 | 1.25 | 1.40 | 1.13 | 0.10 | 0.13 | 0.08 | — |
| Inventory Turnover | 9.37 | 9.37 | 5.92 | 7.42 | 9.89 | 7.34 | 8.22 | 9.38 | 12.00 | 0.90 | — |
| Days Sales Outstanding | — | 31.90 | 60.65 | 32.02 | 96.85 | 91.69 | 128.15 | 8.22 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 0.2% | — | — | — | — | — |
| FCF Yield | — | — | — | — | 0.3% | 0.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $2M | $2M | $2M | $1M | $1M | $857650 | $719743 | $552802 | $621896 | $621896 |
Liquidity and operational viability
As reported in recent financial statements, BGLC's gross margin plummeted to -99.5% in 2026Q1, a stark departure from the 14.62% average observed in prior periods, signaling a complete loss of pricing power and an inability to cover basic procurement costs for its industrial chemical segment.
The shift into negative gross margins suggests that the company is currently selling inventory below its cost of acquisition, which is unsustainable for a distribution-heavy business model. Investors should monitor whether this reflects a strategic liquidation of legacy assets or a fundamental breakdown in the company's supply chain economics.
Based on BGLC's reported figures, ROIC has consistently trended downward, reaching -8.0% in 2026Q1, which indicates that the company is failing to generate adequate returns on its invested capital compared to its historical performance and broader industry benchmarks for diagnostic research firms.
The persistent negative ROIC suggests that capital allocated toward the liquid biopsy diagnostic segment is not yet yielding a return that offsets the losses from the chemical distribution business. This trend warrants further investigation into whether the company's R&D investments are creating any tangible economic value or merely consuming cash.
According to recent quarterly filings, the cash conversion cycle has ballooned to 2,880 days in 2026Q1, a massive increase from the 19-day cycle observed in 2023Q4, indicating severe inefficiencies in managing inventory and collecting payments from the company's industrial customer base.
The extreme volatility in the cash conversion cycle suggests that the company is struggling to move its chemical inventory, which may be becoming obsolete or difficult to sell in the current market. This inefficiency effectively traps liquidity that is desperately needed to fund the company's high-tech diagnostic R&D initiatives.
As indicated by the company's financial data, the current ratio of 6.52 in 2026Q1 appears deceptively high, as it is heavily skewed by stagnant inventory and receivables that may not be readily convertible to cash to meet immediate operational obligations.
While the balance sheet shows a nominal liquidity cushion, the rapid depletion of cash reserves in the face of persistent operating losses suggests that the company's liquidity position is more vulnerable than the headline ratios imply. Investors should monitor the burn rate closely, as the current cash position may not support long-term R&D without external financing.
The market's tendency to apply a biotech-style valuation to BGLC is fundamentally flawed, as it obscures the reality that the company functions primarily as a distressed industrial wholesaler with a high-risk, unproven diagnostic call option that currently lacks the scale to drive meaningful revenue.
Analysts should prioritize a sum-of-the-parts valuation that treats the chemical segment as a declining industrial asset and the diagnostic segment as a venture-stage project. Relying on standard P/S or P/B multiples for this business model ignores the structural margin erosion and the high probability of future dilutive financing.
Includes 30+ ratios · 10 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BGLC stock.
BioNexus Gene Lab Corp.'s current P/E ratio is -1.2x. This places it at the 50th percentile of its historical range.
BioNexus Gene Lab Corp.'s return on equity (ROE) is -35.2%. The historical average is -36.9%.
Based on historical data, BioNexus Gene Lab Corp. is trading at a P/E of -1.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
BioNexus Gene Lab Corp. has 14.6% gross margin and -42.5% operating margin.